Fertomid 25 mg (Clomiphene)

Product Overview

Fertomid 25 mg manufactured by Cipla Limited is a prescription medication indicated for female infertility associated with ovulatory dysfunction. Each strip contains ten tablets delivering 25 milligrams of clomiphene citrate. The product is supplied in pack sizes of 60 90 and 120 tablets allowing clinicians to tailor therapy to individual patient needs.

What is Fertomid 25 mg (Clomiphene)

Fertomid 25 mg is the brand name for clomiphene citrate a selective estrogen receptor modulator that blocks estrogen receptors in the hypothalamus leading to increased release of gonadotropin releasing hormone GnRH This stimulates the pituitary to secrete follicle stimulating hormone FSH and luteinizing hormone LH promoting the development of ovarian follicles The 25 mg strength is often used as a starting dose or as a reduced dose for patients who may be sensitive to higher formulations

Uses and Benefits

Fertomid 25 mg is prescribed for the treatment of ovulatory infertility in women with polycystic ovary syndrome PCOS hypothalamic amenorrhea or other endocrine disorders that impair regular ovulation By inducing the development of multiple ovarian follicles the medication increases the probability of conception when combined with timed intercourse or intrauterine insemination IUI Clinical studies have demonstrated that treatment cycles using clomiphene citrate can achieve live birth rates ranging from 5 percent to 12 percent per cycle depending on age baseline ovarian reserve and protocol specifics In addition to its primary indication Fertomid is occasionally employed off label in assisted reproductive technologies such as in vitro fertilization IVF to stimulate the growth of multiple follicles though higher doses are typically required For a detailed overview of polycystic ovary syndrome refer to the National Institutes of Health resource National Institutes of Health

How It Works

Clomiphene citrate exerts its pharmacodynamic effect by binding to estrogen receptors in the hypothalamus and pituitary gland This antagonistic activity prevents the negative feedback of endogenous estrogen leading to up regulation of GnRH pulsatility Consequently the anterior pituitary releases increased amounts of FSH and LH which are essential for follicular recruitment and maturation The surge in LH triggers ovulation approximately 36 hours after the final exogenous dose providing a predictable window for conception attempts Because the drug is a SERM its tissue specific agonist or antagonist activity varies In the ovary it acts as an antagonist promoting follicular growth while in other tissues it may exhibit partial agonist effects This dual mechanism underlies its efficacy in stimulating ovulation without directly influencing ovarian androgen production

Dosage Guidelines

The standard therapeutic regimen for Fertomid 25 mg in the treatment of ovulatory dysfunction typically begins with a single oral dose of 25 mg taken daily for five consecutive days usually starting on the fifth day of the menstrual cycle If ovulation does not occur the clinician may increase the dose to 50 mg daily for five days in subsequent cycles with a maximum recommended cumulative dose of 150 mg over six cycles Patients with compromised hepatic function or those at higher risk of ovarian hyperstimulation may require dose reduction and close monitoring via transvaginal ultrasound and serum estradiol measurements It is essential that dosage adjustments be made only under the guidance of a qualified healthcare professional as inappropriate dosing can elevate the risk of multiple gestations and ovarian cysts

Side Effects

Like all pharmacologic agents Fertomid 25 mg can be associated with adverse effects most of which are mild and self limiting Commonly reported symptoms include hot flashes abdominal discomfort breast tenderness and visual disturbances such as blurred vision or photopsia Less frequent but clinically significant events comprise ovarian hyperstimulation syndrome OHSS characterized by pelvic pain ascites and rapid weight gain as well as thromboembolic phenomena which require immediate medical attention Mood alterations including irritability or depression have also been documented Patients should be advised to report any persistent or severe side effects to their physician promptly For a comprehensive list of adverse reactions refer to the official prescribing information or reputable drug databases such as Drugs com

Warnings and Precautions

Fertomid 25 mg is contraindicated in individuals with known hypersensitivity to clomiphene citrate or any component of the formulation as well as in patients with hepatic impairment ovarian cysts unrelated to polycystic ovary syndrome or abnormal uterine bleeding of undetermined etiology Prior to initiation a thorough evaluation should include a pelvic examination baseline hormonal assays and when indicated imaging to exclude structural abnormalities Concomitant use with other ovulation inducing agents or hormonal therapies may increase the likelihood of multiple pregnancies so careful counseling regarding reproductive risks is mandatory Women who are pregnant breastfeeding or have a history of estrogen dependent tumors should not use this medication Ongoing monitoring of ovarian size and serum estradiol is recommended to mitigate the potential for OHSS especially in patients with polycystic ovary syndrome For additional safety information consult the U.S. Food and Drug Administration U.S. Food and Drug Administration

Frequently Asked Questions

1. Question: How should Fertomid 25 mg be stored
   Answer: Store the tablets at room temperature away from moisture and heat and keep the strip sealed until ready for use
2. Question: Can Fertomid be used by women who have already experienced menopause
   Answer: No the medication is indicated only for women with retained ovarian function it is not effective or appropriate for post menopausal patients
3. Question: Is it safe to take Fertomid while undergoing other fertility treatments
   Answer: It may be combined with intrauterine insemination or controlled ovarian stimulation protocols but concurrent use with other ovulation agents should only occur under medical supervision to avoid excessive follicular development
4. Question: What monitoring is required during a treatment cycle
   Answer: Clinicians typically perform transvaginal ultrasound on the day of expected ovulation and may check serum estradiol levels to confirm adequate follicular growth and to detect any signs of ovarian hyperstimulation
5. Question: Are there lifestyle changes that can improve response to Fertomid
   Answer: Maintaining a healthy body mass index managing stress and ensuring adequate nutrition can enhance ovulatory response however any supplement or exercise regimen should be discussed with a healthcare provider